Remove 2024 Remove Dosage Remove Labelling
article thumbnail

Alembic secures USFDA approval for Diltiazem Hydrochloride extended-release capsules

Express Pharma

The label provides a detailed indication. Diltiazem Hydrochloride Extended-Release Capsules USP in the 120 mg, 180 mg, and 240 mg dosages have an estimated market size of US$ 28.2 million for the twelve months ending June 2024, according to IQVIA. It is also indicated for the management of chronic stable angina.

Dosage 97
article thumbnail

OPDP Says TV Ad is Out of Bounds with Fourth Untitled Letter of 2024

FDA Law Blog: Biosimilars

By Sarah Wicks & Dara Katcher Levy — FDA’s Office of Prescription Drug Promotion (OPDP) has issued its fourth Untitled Letter of 2024 – this one to AbbVie, Inc. The approved labeling for UBRELVY includes a warning and precaution regarding hypersensitivity reactions, with the most common adverse reactions being nausea and somnolence.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The IMA Group at ACHEMA 2024 : All-In-One solutions for the pharmaceutical sector

European Pharmaceutical Review

Meeting the Divisions at ACHEMA 2024 IMA Active The ideal partner for each solid dose processing phase: granulation, tableting, capsule filling and banding, weight checking, coating, handling and washing. customers will have the opportunity to experience first hand various digital solutions aimed at reducing maintenance costs and downtime.

article thumbnail

Sustainability continues to steer pharmaceutical packaging market

European Pharmaceutical Review

percent between 2024 and 2033. Packaging types generating demand in the market include tamper-proofing drug packaging against counterfeiting, as well as single-dosage packaging, according to the research. The worldwide pharmaceutical container packaging market is expected to rise in revenue from $104.12

article thumbnail

Micromedex

RX Note

In November 2024, a new Micromedex app was introduced to deliver more efficient access to all Micromedex content, including Drug Reference, Drug Interactions, IV Compatibility and calculators. In my experience, there are increasingly more off-label uses and dosages included in this resource.

Dosage 52
article thumbnail

FDA proposes removal of oral Phenylephrine from OTC nasal decongestant products

Express Pharma

On 7 November 2024, the U.S. The committee reviewed new data regarding the oral administration of phenylephrine and unanimously concluded that the current scientific evidence does not support its effectiveness at the recommended OTC dosage. Theresa Michele, M.D.,

Dosage 77
article thumbnail

Novartis gets positive CHMP opinion for Kisqali in early breast cancer

Pharmaceutical Business Review

The positive opinion from CHMP is based on the results from the Phase III NATALEE trial, which is a global, multi-centre, open-label study. The safety profile of Kisqali at the 400mg dosage was also highlighted as well-tolerated, with most adverse events being of low grade. This also includes those with node-negative disease.

Dosage 52